Multiple Myeloma Support + Trials

What's the purpose of this trial?

The goal of this clinical trial is to find the best dose and learn more about the safety and effectiveness of maplirpacept (PF-07901801) in patients with advanced hematologic malignancies, including Lymphoma, Leukemia, and Multiple Myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is being conducted in two phases, 1a and 1b. During Phase 1a, researchers gave participants different doses of maplirpacept (PF-07901801) to determine which dose is best tolerated. During Phase 1b, researchers will give the best doses of maplirpacept (PF-07901801) from Phase 1a, alone or in combination with other medicines, to a larger group of participants to further evaluate its safety and effectiveness.

This trial is open-label, which means that both participants and researchers will know which group they are placed in, and what treatments and doses they are receiving. Participants in this study may continue to receive study treatment unless they develop bad side effects, or their cancer gets worse.

Phase 1b of this trial is further separated into smaller groups, called cohorts. The cohort of this trial you may join depends on your diagnosis and other factors.

Reimbursement for study-related travel expenses may be available.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

• have measurable disease as defined by the trial criteria. The measurable disease criteria depends on your diagnosis, and which specific cohort you may qualify for.
• do not have central nervous system involvement of your cancer.
• have not received a stem cell transplant in the last 90 days.
• have not previously received treatment with an anti-CD47 and anti-SIRPa therapy.
• are not refractory to or intolerant to anti-CD38 therapy, and have not received anti-CD38 therapy in the previous 60 days.